5/9/2025

Janusmed sex and gender

Janusmed sex and gender – vigabatrin

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Vigabatrin

Vigabatrin

Class : C

Show all info

Print

Contact us

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SABRIL (vigabatrin). Drugs@FDA [www]. [updated 2009-11-12, cited 2019-10-04].

  2. Sabril (vigabatrin). DailyMed [www]. US National Library of Medicine. [updated 2019-08-14, cited 2019-10-04].

  3. Sabrilex (vigabatrin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2018-06-07, cited 2019-10-04].

  4. Nielsen JC, Kowalski KG, Karim A, Patel M, Wesche DL, Tolbert D. Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. Clin Pharmacokinet. 2014;53(11):1019-31.

  5. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37 Suppl 6:S34-44.

  6. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs. 2001;15:217-30.

  7. Wild JM, Ahn HS, Baulac M, Bursztyn J, Chiron C, Gandolfo E et al. Vigabatrin and epilepsy: lessons learned. Epilepsia. 2007;48(7):1318-27.

  8. Westall CA, Wright T, Cortese F, Kumarappah A, Snead OC, Buncic JR. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. Neurology. 2014;83(24):2262-8.

  9. EMA. Opinion of the Committee for Proprietary Medicinal Products pursuant to article 12 of council directive 75/319/eec as amended, for Vigabatrin. 1999.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SABRIL (vigabatrin). Drugs@FDA [www]. [updated 2009-11-12, cited 2019-10-04].
  2. Sabril (vigabatrin). DailyMed [www]. US National Library of Medicine. [updated 2019-08-14, cited 2019-10-04].
  3. Sabrilex (vigabatrin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2018-06-07, cited 2019-10-04].
  4. Nielsen JC, Kowalski KG, Karim A, Patel M, Wesche DL, Tolbert D. Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. Clin Pharmacokinet. 2014;53(11):1019-31.
  5. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996;37 Suppl 6:S34-44.
  6. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs. 2001;15:217-30.
  7. Wild JM, Ahn HS, Baulac M, Bursztyn J, Chiron C, Gandolfo E et al. Vigabatrin and epilepsy: lessons learned. Epilepsia. 2007;48(7):1318-27.
  8. Westall CA, Wright T, Cortese F, Kumarappah A, Snead OC, Buncic JR. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. Neurology. 2014;83(24):2262-8.
  9. EMA. Opinion of the Committee for Proprietary Medicinal Products pursuant to article 12 of council directive 75/319/eec as amended, for Vigabatrin. 1999.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]